Full text is available at the source.
Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone
Gut bacteria changes in obese PCOS patients treated with metformin alone or combined with exenatide
AI simplified
Abstract
In a study of 29 patients with obesity and polycystic ovary syndrome, both exenatide combined with metformin and metformin alone improved metabolic markers and gut microbiota composition.
- Body mass index (BMI), total testosterone (TT), HbA1c, and HDL cholesterol levels were significantly improved in both treatment groups.
- Both groups showed an increase in the abundance of specific gut bacteria, such as Bacteroidetes and certain probiotics, after treatment.
- Distinct differences in gut microbial species were observed between the two groups; for example, Clostridium and Fusobacterium predominated in the metformin group.
- The combination treatment resulted in a higher presence of probiotic species, including Bifidobacterium and Prevotella, compared to metformin alone.
- Both treatment regimens positively affected the diversity and abundance of intestinal flora in patients with obesity and PCOS.
AI simplified